SHR4640
Phase 2Small molecule
SHR4640 is one of 11 small molecule programs targeting Hyperuricemia. It is currently in Phase 2.
1
Indications
19
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Hyperuricemia
#DrugCompanyPhaseTrials
1Uloric
TakedaApproved
Medrol
PfizerApproved
Farxiga
AstraZenecaApproved
Alli
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Tekturna
Tibotec Pharmaceuticals, IrelandApproved
Decadron
AAspen Global Incorporated
Approved
Dotinurad
EisaiPhase 3
Alka-Seltzer
AAbbott
Preclinical
SHR4640
JJiangsu HengRui Medicine Co., Ltd.
Phase 2
Zurampic
IIronwood Pharmaceuticals, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hyperuricemia5 trials
Efficacy and Safety2 trials
Interaction2 trials
Oral2 trials
6 more indications
Renal insufficiency1 trial
Adult1 trial
ESS1 trial
Hepatic Impairment1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SHR4640. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details